This once-hypothetical scenario is fast becoming a reality. European cannabis reform has become a question of how, not if.

In a historic event that will be closely watched across the world, Canada today becomes the first G7 country to legalise cannabis for recreational use.

The UK government has laid historic new regulations rescheduling cannabis-based medicine, which will come into force on 1st November 2018.

Hanway Associates CEO George McBride spoke at the Conservative Party Conference and Cannabis Invest UK this week on developments in the UK and European Cannabis industry.

On September 21st the UK government announced how they would define cannabis-based products for medicinal use. Following the conclusion of the two part review by the Chief Medical Officer and the ACMD on July 25th, Home Secretary Sajid Javid committed to swift action on the matter, and promised that these products would be lawful by autumn.

On Monday 10th September, the National Agency for Health and Medicines (ANSM) announced the creation of a special committee to review the evidence supporting the effectiveness of medical cannabis.

This is the demand on every Canadian cannabis consumer’s lips at the moment, and one that will remain a chief concern when the adult use market goes legal this summer. 

Despite cannabis being the most used illicit drug in the UK, little is known about the true scale of the UK cannabis market.

The clock is ticking. Canadian provinces have less than a year in which to decide how, where and by whom cannabis will be sold.

Hanway Associates partner George discussing the risks & opportunities for investors in the growing North American cannabis industry.

Hanway Associates partner Dr Henry Fisher writing about 'Spice' in The Guardian